DoD Multiple Sclerosis, Early Investigator Research Award | HT9425 23 MSRP EIRA

Opportunity Information: Apply for HT9425 23 MSRP EIRA

The Department of Defense (DoD), through the U.S. Army Medical Research Acquisition Activity (USAMRAA), offered the Multiple Sclerosis Research Program (MSRP) Early Investigator Research Award (EIRA) under Funding Opportunity Number HT9425-23-MSRP-EIRA. The core purpose of this mechanism is to build the next generation of multiple sclerosis (MS) researchers by funding MS-focused projects led by investigators who are still early in their careers, while also requiring structured mentorship and a clear plan for professional growth. It is positioned as both a research award and a career development opportunity, meaning the program is looking not only at what science will be done, but also at how the applicant will develop into an independent MS investigator.

A defining feature of the EIRA is that the postdoctoral-level investigator serves as the Principal Investigator (PI) and is expected to take primary ownership of the application and the proposed work. The PI must show strong potential and genuine commitment to building a research career centered on MS, but the program explicitly does not require prior MS-specific research experience. In practice, that means a talented early-career scientist coming from an adjacent field can be competitive if the proposal is well-justified, MS-relevant, and paired with strong mentorship that bridges any gaps in disease-area background.

Mentorship is not optional under this award. Each application must name at least one Mentor whose expertise aligns with the proposed project and who has demonstrated MS research and mentoring experience through active funding, recent publications, and a track record of successfully guiding trainees. The opportunity allows the primary Mentor to be a junior faculty member, but if that is the case, the PI is encouraged to add a secondary Mentor with a deeper, more established record in MS research and mentorship. Across the mentoring team, the DoD is clearly signaling that it wants a realistic, hands-on commitment to moving the PI toward independence, not a nominal supervisory role.

In addition to the research plan, the application must include an individualized Researcher Development Plan that is explicitly MS-focused. This plan needs to spell out, in concrete terms, how the PI will gain the skills, technical competencies, and field-specific expertise required to execute the project successfully and progress toward becoming an independent MS researcher. The FOA emphasizes the importance of a supportive environment for both mentoring and research. If the PI's home institution lacks certain resources or expertise, the program allows those shortcomings to be addressed through collaborations with other institutions. When substantial resources from another institution will be used, the PI is strongly encouraged to name a secondary Mentor at that collaborating site, reinforcing the expectation that training and oversight follow the work wherever it is performed.

On the science side, the research project must be aligned with the FY23 MSRP EIRA Focus Areas and should address critical needs of the MS community. The program expects a strong scientific rationale and rigorous experimental methodology, with evidence that the applicant has thought deeply about the problem being tackled. Reviewers are looking for feasibility as well as ambition: the design and methods should be clearly defined, the milestones should make sense, and the application should present a credible plan for how the project goals will be achieved within the award period. The FOA also asks applicants to articulate both short-term outcomes (what the project will produce during the funded period, such as data sets, mechanistic insights, preliminary validation, new methods, or biomarkers) and long-term gains (how those results could launch future studies and ultimately advance MS research and/or patient care).

The opportunity includes a couple of topic-specific expectations that applicants must plan for if relevant. For applications under the "Correlates of Disease Activity and Progression in MS" focus area, the applicant must demonstrate access to the needed specimens and/or cohort data, typically supported by formal documentation such as letters confirming access. For projects using animal models of MS, the DoD expects applicants to choose models carefully and to justify why the selected model or models are appropriate and relevant to the specific aspect of human MS being studied, rather than using an animal system by default without a clear translational argument.

Administratively, this was a discretionary funding opportunity using either a grant or cooperative agreement instrument, categorized under Science and Technology and other Research and Development (CFDA 12.420). Eligibility was listed as unrestricted (open to any type of entity), subject to any additional eligibility clarifications in the full announcement. The posting date was April 14, 2023, with an original closing date of October 6, 2023. The announcement indicated an expectation of approximately six awards. The award ceiling was listed as 0 in the provided record, which usually signals that the cap was not reflected in that data field and would need to be confirmed in the full FOA or associated program guidance.

Overall, the EIRA is best understood as a mentored early-career MS research launchpad: it funds a defined MS-focused project, but it places equal weight on the applicant's trajectory, the strength and suitability of the mentoring team, the quality of the development plan, and the likelihood that the award will position the PI to become a productive, independent MS investigator with a sustainable research direction.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Multiple Sclerosis, Early Investigator Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 14, 2023.
• Applicants must submit their applications by Oct 06, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 MSRP EIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: